We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
FIG. 5.

FIG. 5. From: Diabetes-Specific HLA-DR-Restricted Proinflammatory T-Cell Response to Wheat Polypeptides in Tissue Transglutaminase Antibody-Negative Patients With Type 1 Diabetes.

Role of HLA-DR in the type 1 diabetes T-cell and cytokine response to WPs. A: The T-cell response to wheat protein (6.2 μg/ml) was calculated as CDI in 14 patients and compared with cells cultured in the presence of anti–HLA-DR monoclonal antibody (5 μg/ml) or with isotype control antibody. B: Cytokine profiles of supernatants from WP-stimulated PBMNC of patients were evaluated in the absence and presence of monoclonal HLA-DR antibodies using Th1/Th2 CBAs for IFN-γ, IL-4, TNF, IL-10, and IL-6 or an ELISA kit for IL-17A.

Majid Mojibian, et al. Diabetes. 2009 August;58(8):1789-1796.
2.
FIG. 3.

FIG. 3. From: Diabetes-Specific HLA-DR-Restricted Proinflammatory T-Cell Response to Wheat Polypeptides in Tissue Transglutaminase Antibody-Negative Patients With Type 1 Diabetes.

WP-stimulated cytokine secretion by PBMNC at day 8 of culture. Box and Whisker plots with individual values for control and diabetic subjects. IFN-γ, TNF, IL-6, IL-4, and IL-10 were measured by flow CBA. IL-17A was measured by ELISA. Each plot includes the mean (dashed line), median (solid line), distribution, and range. (For IL-4, the difference between control and type 1 diabetic [T1D] subjects is significant when the circled outlier value in the control group is removed [P = 0.03].)

Majid Mojibian, et al. Diabetes. 2009 August;58(8):1789-1796.
3.
FIG. 1.

FIG. 1. From: Diabetes-Specific HLA-DR-Restricted Proinflammatory T-Cell Response to Wheat Polypeptides in Tissue Transglutaminase Antibody-Negative Patients With Type 1 Diabetes.

Antigen-specific CD3+ T-cell proliferation. 1.2 × 106 CFSE-labeled PBMNCs from patients with type 1 diabetes (T1D) or healthy control subjects were cultured for 8 days in the absence or presence of different concentrations of WPs. On day 8, cells were stained with Cy-chrome conjugated anti-CD3 monoclonal antibody. CDI was calculated based on a fixed number of 5,000 CD3+ CFSEbright cells using the following formula: CDI = number of CD3+, CFSEdim cells with antigen/number of CD3+, CFSEdim cells without antigen (medium). The horizontal line indicates the mean.

Majid Mojibian, et al. Diabetes. 2009 August;58(8):1789-1796.
4.
FIG. 2.

FIG. 2. From: Diabetes-Specific HLA-DR-Restricted Proinflammatory T-Cell Response to Wheat Polypeptides in Tissue Transglutaminase Antibody-Negative Patients With Type 1 Diabetes.

T-cell proliferation in response to WPs and other antigens or mitogen. 1.2 × 106 CFSE-labeled PBMNCs from patients with type 1 diabetes (T1D) or healthy control subjects were cultured for 8 days in the absence or presence of WP, ovalbumin (OVA), gliadin, 33-mer, insulin, tetanus toxoid (TT), or phytohemagglutinin (PHA) (see research design and methods for details). On day 8, cells were stained with Cy-chrome–conjugated anti-CD3 monoclonal antibody. CDI was calculated. A CDI value greater than the control mean + 3 SD (CDI >14.6) was used to define a positive response to WP. P values indicate statistical difference compared with control subjects. The horizontal lines indicate the means.

Majid Mojibian, et al. Diabetes. 2009 August;58(8):1789-1796.
5.
FIG. 4.

FIG. 4. From: Diabetes-Specific HLA-DR-Restricted Proinflammatory T-Cell Response to Wheat Polypeptides in Tissue Transglutaminase Antibody-Negative Patients With Type 1 Diabetes.

Graphic representation of the relationship between wheat-induced T-cell response and high-resolution HLA diabetes risk alleles. Box and Whisker plots with individual values for diabetic subjects. Each plot includes the mean (bold line), median (solid thin line), distribution, and range. A: Distribution of T-cell proliferation (CDI) to WP in type 1 diabetic patients with HLA-DRB1*03 and HLA-DRB1*04 or in those heterozygous for HLA-DRB1*03/*04. A CDI value greater than mean + 3 SD of the control group (CDI >14.6, dashed line) was used to define a positive proliferation response. One of the type 1 diabetic patients with HLA-DRB1*03+/*04 showed positive responses to WP (○). Type 1 diabetic patients who carried one risk allele HLA-DRB1*04 (10 of 20) or patients who carried both risk genes HLA-DRB1*03/*04 (9 of 12) showed positive reactivity to WP. High-resolution results of HLA-DR are labeled beside each individual. B: Distribution of T-cell proliferation (CDI) to WP in type 1 diabetic patients with HLA-DQB1*02 and HLA-DQB1*03 or in those heterozygous for HLA-DQB1*02/*03. High-resolution analyses for HLA-DQB1*02 and *03 are labeled beside each symbol. ↓ (beside 0201) means all individuals in the column carry HLA-DQB1*0201. (Three of the 42 type 1 diabetic individuals are neither DR3 nor DR4, and therefore they are not included in this figure. One of the seven individuals with DR3/non-DR4 in the left panel is heterozygous for DQ*02/*03 and was therefore placed in the middle column in the right panel [DQ*02*03]. Differences in high-resolution haplotypes between responders and nonresponders were not evaluated statistically because of the small sample size.)

Majid Mojibian, et al. Diabetes. 2009 August;58(8):1789-1796.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk